<DOC>
	<DOCNO>NCT00613626</DOCNO>
	<brief_summary>At point treatment extensive stage SCLC , reach plateau survival conventional chemotherapy newer regimens greatly need . It note patient increase VEGF level poorer prognosis . Anti-angiogenic agent hold significant promise treatment patient extensive stage SCLC . ZD6474 , new inhibitor VEGFR-2 , show favorable action NSCLC .</brief_summary>
	<brief_title>Cisplatin + Etoposide +/- Concurrent ZD6474 Previously Untreated Extensive Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>OUTLINE : This multi-center study . Arm A : Cisplatin 60mg/m2 Day 1 + Etoposide 120mg/m2 Day 1,2,3 + Placebo oral daily give continuously duration study Arm B : Cisplatin 60mg/m2 Day 1 + Etoposide 120mg/m2 Day 1,2,3 + ZD6474 100mg oral daily give continuously duration study For arm , PE toxicity evaluation prior cycle disease assessment image every 2 cycle . Patients non-PD acceptable toxicity continue protocol therapy ; patient progressive disease excessive toxicity take treatment . Cycles repeat every 21 day total 4 cycle . ECOG Performance Status 0 1 Life Expectancy : Not specify Hematopoietic : - Platelets &gt; 100K/mm3 - Absolute neutrophil count ( ANC ) &gt; 1.5K/mm3 Hepatic : - Bilirubin &lt; 1.5 x ULN - Aspartate aminotransferase ( AST ) &lt; 2.5 x ULN &lt; 5 x ULN judge investigator relate liver metastases - Alkaline phosphatase &lt; 2.5 x ULN &lt; 5 x ULN judge investigator relate liver metastases Renal : - Serum creatinine &lt; 1.5 x ULN Calculated creatinine clearance &gt; 45 cc/min use Cockcroft-Gault formula Cardiovascular : - No clinically significant cardiac event myocardial infarction ; New York Heart Association ( NYHA ) classification heart disease &gt; 2 ( see SPM ) within 3 month prior registration protocol therapy - No presence cardiac disease , opinion Investigator , increase risk ventricular arrhythmia . - No history arrhythmia ( multifocal premature ventricular contraction ( PVCs ) , bigeminy , trigeminy , ventricular tachycardia , uncontrolled atrial fibrillation ) symptomatic require treatment ( CTCAE grade 3 ) asymptomatic sustain ventricular tachycardia . Atrial fibrillation , control medication permit .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Histological cytological proof chemotherapynaïve , extensive , small cell lung cancer . Measurable disease accord RECIST obtain image within 28 day prior register protocol therapy . Written inform consent HIPAA authorization release personal health information . Age 18 year old time consent . Potassium ≥4.0 mmol/L &lt; 5.5mmol/L ( supplementation allow ) . Calcium within normal range ( supplementation allow ) . Magnesium within normal range ( supplementation allow ) . No prior EGFR inhibitor antiangiogenic agent allow . No prior hormonal therapy . No symptomatic brain metastasis . No clinically significant infection judge treat investigator . No evidence severe uncontrolled systemic disease concurrent condition Investigator 's opinion make undesirable subject participate trial would jeopardize compliance protocol . No previous history QTc prolongation result medication require discontinuation medication . No congenital long QT syndrome know 1st degree relative unexplained sudden death 40 year age . No presence leave bundle branch block ( LBBB . ) No QTc Bazett 's correction unmeasurable , ≥480 msec screen ECG obtain within 7 day prior registration protocol therapy . If subject QTc ≥480 msec screen ECG , screen ECG may repeat twice ( least 24 hour apart ) . The average QTc three screen ECGs must &lt; 480 msec order subject eligible study . No concomitant ( within 14 day prior registration protocol therapy ) medication associate Torsades de Pointes cause QTc prolongation , allow . Medications prolong QT , strictly associate Torsades , allow medically necessary require increase ECG electrolyte monitoring . No uncontrolled hypertension ( systolic blood pressure great 160 mm Hg diastolic blood pressure great 100 mm Hg ) . No currently active diarrhea may affect ability absorb ZD6474 . No prior malignancy allow except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , Gleason &lt; grade 7 prostate cancer , cancer subject diseasefree least 5 year . Major surgery must complete great 28 day prior registration protocol therapy heal surgical incision require . No concomitant ( within 14 day prior registration protocol therapy ) medication potent inducer ( rifampicin , rifabutin , phenytoin , carbamazepine , phenobarbital St. John 's Wort ) CYP3A4 function . Females childbearing potential male must willing use effective method contraception ( hormonal barrier method birth control ; abstinence ) time consent sign 8 week treatment discontinuation . Females childbearing potential must negative pregnancy test within 7 day prior register protocol therapy . Females must breastfeed .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Extensive Stage</keyword>
	<keyword>Untreated</keyword>
</DOC>